keyword
MENU ▼
Read by QxMD icon Read
search

Fidaxomicin

keyword
https://www.readbyqxmd.com/read/28433406/results-of-the-implementation-of-a-multidisciplinary-programme-of-faecal-microbiota-transplantation-by-colonoscopy-for-the-treatment-of-recurrent-clostridium-difficile-infection
#1
Antonio López-Sanromán, Enrique Rodríguez de Santiago, Javier Cobo Reinoso, Rosa Del Campo Moreno, José Ramón Foruny Olcina, Sergio García Fernández, Ana García García de Paredes, Lara Aguilera Castro, Carlos Ferre Aracil, Agustín Albillos Martínez
INTRODUCTION: Recurrent Clostridium difficile infection (CDI) is common and often difficult to manage. Faecal microbiota transplant (FMT) is an effective therapeutic tool in these cases, although its applicability and effectiveness in Spain is currently unknown. AIM: To analyse the technical aspects, safety and effectiveness of the first consolidated FMT programme in Spain. METHODS: Retrospective descriptive study of all patients with recurrent CDI treated with FMT performed by colonoscopy in a tertiary centre after the implementation of a multidisciplinary protocol between March 2015 and September 2016...
April 19, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/28407067/evaluation-of-a-second-sign-process-for-antimicrobial-prior-authorization
#2
Aimee M Dassner, Jennifer E Girotto
Background.: A second-sign prospective restriction of select broad-spectrum antimicrobials was fully implemented in January 2015 as a pediatric antimicrobial stewardship program (ASP) initiative to help ensure the most appropriate empiric use of ceftaroline, cefepime, fidaxomicin, linezolid, and vancomycin (intravenous). The objective of this evaluation is to assess the effectiveness of a forced second-sign process in the electronic medical record as a pediatric ASP strategy. We anticipated that the second-sign process for antibiotics would increase the appropriateness of empiric antibiotic use, as defined by preapproved criteria, clinical pathways, national guidelines, and pediatric-specific infectious diseases reference texts, while not causing significant delay in the initial administration of antibiotic therapy...
April 12, 2017: Journal of the Pediatric Infectious Diseases Society
https://www.readbyqxmd.com/read/28404671/an-update-on-antimicrobial-resistance-in-clostridium-difficile-resistance-mechanisms-and-antimicrobial-susceptibility-testing
#3
Zhong Peng, Dazhi Jin, Hyeun Bum Kim, Charles W Stratton, Bin Wu, Yi-Wei Tang, Xingmin Sun
Oral antibiotics such as metronidazole, vancomycin and fidaxomicin are therapies of choice for CDI. Several important mechanisms for C. difficile antibiotic resistance have been described; these include the acquisition of antibiotic resistance genes via transfer of mobile genetic elements, selective pressure in vivo resulting in gene mutations, altered expression of redox-active proteins, iron metabolism and DNA repair, as well as biofilm formation. This update summarizes new information published since 2010 on phenotypic and genotypic resistance mechanisms in C...
April 12, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28347318/pharmacokinetics-of-surotomycin-from-phase-1-single-and-multiple-ascending-dose-studies-in-healthy-volunteers
#4
Gurudatt Chandorkar, Qiao Zhan, Julie Donovan, Shruta Rege, Hernando Patino
BACKGROUND: Surotomycin, a novel, orally administered, cyclic, lipopeptide antibacterial in development for the treatment of Clostridium difficile-associated diarrhea, has demonstrated minimal intestinal absorption in animal models. METHODS: Safety, tolerability, and plasma pharmacokinetics of single and multiple ascending oral doses (SAD/MAD) of surotomycin in healthy volunteers were characterized in two randomized, double-blind, placebo-controlled, phase 1 studies...
March 28, 2017: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28332133/molecular-typing-and-antimicrobial-susceptibility-testing-to-six-antimicrobials-of-clostridium-difficile-isolates-from-three-czech-hospitals-in-eastern-bohemia-in-2011-2012
#5
V Beran, E J Kuijper, C Harmanus, I M Sanders, S M van Dorp, C W Knetsch, J Janeckova, A Seidelova, L Barekova, J Tvrdik, D Chmelar, I Ciznar
In 2011-2012, a survey was performed in three regional hospitals in the Czech Republic to determine the incidence of Clostridium difficile infections (CDIs) and to characterize bacterial isolates. C. difficile isolates were characterized by PCR ribotyping, toxin genes detection, multiple-locus variable-number tandem-repeat analysis (MLVA), and antimicrobial susceptibility testing to fidaxomicin, vancomycin, metronidazole, clindamycin, LFF571, and moxifloxacin using agar dilution method. The incidence of CDI in three studied hospitals was 145, 146, and 24 cases per 100,000 inhabitants in 2011 and 177, 258, and 67 cases per 100,000 inhabitants in 2012...
March 22, 2017: Folia Microbiologica
https://www.readbyqxmd.com/read/28331803/ivig-a-cure-to-severe-refractory-nap-1-clostridium-difficile-colitis-a-case-of-successful-treatment-of-severe-infection-which-failed-standard-therapy-including-fecal-microbiota-transplants-and-fidaxomicin
#6
Kelley Coffman, Xian Jie Cindy Chen, Charles Okamura, Eddie Louie
The mainstay treatment of Clostridium difficile infections (CDI) is antimicrobials with growing support for fecal microbiota transplants. We report the first case of an elderly man with severe refractory NAP-1 pseudomembranous CDI who failed all medical therapy and two fecal transplants with response only seen after administration of intravenous immunoglobulin.
2017: IDCases
https://www.readbyqxmd.com/read/28299963/cost-effectiveness-analysis-on-the-use-of-fidaxomicin-and-vancomycin-to-treat-clostridium-difficile-infection-in-france
#7
Maureen Watt, Aurélien Dinh, Alban Le Monnier, Patrick Tilleul
BACKGROUND: Fidaxomicin is a macrocyclic antibiotic with proven efficacy against Clostridium difficile infection (CDI) in adults. It was licensed in France in 2012, but, due to higher acquisition costs compared with existing treatments, healthcare providers require information on its cost/benefit profile. OBJECTIVE: To compare healthcare costs and health outcomes of fidaxomicin and vancomycin, as reference treatment for CDI. METHODS: A Markov model was used to simulate the treatment pathway, over 1 year, of adult patients with CDI receiving fidaxomicin or vancomycin...
March 16, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28286992/cadazolid-for-the-treatment-of-clostridium-difficile
#8
REVIEW
Bradley T Endres, Eugénie Bassères, M Jahangir Alam, Kevin W Garey
Antibiotic development goals for CDI include potent antimicrobial effect against C. difficile, limited killing of host microbiota, potential effect on spores, and ability to interfere with toxin production. Cadazolid, a novel, non-absorbable hybrid antibiotic has many of these criteria. In phase I and II clinical trials, cadazolid was shown to be safe, well tolerated, and efficacious positioning itself as a potential future viable therapeutic option for CDI. Areas covered: This review provides an in-depth evaluation of the chemistry, microbiology, pharmacodynamics, pharmacokinetics, and clinical trial results for cadazolid...
April 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28272217/recurrent-clostridium-difficile-infection-among-medicare-patients-in-nursing-homes-a-population-based-cohort-study
#9
Marya D Zilberberg, Andrew F Shorr, William M Jesdale, Jennifer Tjia, Kate Lapane
We explored the epidemiology and outcomes of Clostridium difficile infection (CDI) recurrence among Medicare patients in a nursing home (NH) whose CDI originated in acute care hospitals.We conducted a retrospective, population-based matched cohort combining Medicare claims with Minimum Data Set 3.0, including all hospitalized patients age ≥65 years transferred to an NH after hospitalization with CDI 1/2011-11/2012. Incident CDI was defined as ICD-9-CM code 008.45 with no others in prior 60 days. CDI recurrence was defined as (within 60 days of last day of CDI treatment): oral metronidazole, oral vancomycin, or fidaxomicin for ≥3 days in part D file; or an ICD-9-CM code for CDI (008...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28257555/antibiotic-treatment-for-clostridium-difficile-associated-diarrhoea-in-adults
#10
REVIEW
Richard L Nelson, Katie J Suda, Charlesnika T Evans
BACKGROUND: Clostridium difficile (C. difficile) is recognized as a frequent cause of antibiotic-associated diarrhoea and colitis. This review is an update of a previously published Cochrane review. OBJECTIVES: The aim of this review is to investigate the efficacy and safety of antibiotic therapy for C. difficile-associated diarrhoea (CDAD), or C. difficile infection (CDI), being synonymous terms. SEARCH METHODS: We searched MEDLINE, EMBASE, CENTRAL and the Cochrane IBD Group Specialized Trials Register from inception to 26 January 2017...
March 3, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28238947/identification-of-novel-mrp3-inhibitors-based-on-computational-models-and-validation-using-an-in-vitro-membrane-vesicle-assay
#11
Izna Ali, Matthew A Welch, Yang Lu, Peter W Swaan, Kim L R Brouwer
INTRODUCTION: Multidrug resistance-associated protein 3 (MRP3), an efflux transporter on the hepatic basolateral membrane, may function as a compensatory mechanism to prevent the accumulation of anionic substrates (e.g., bile acids) in hepatocytes. Inhibition of MRP3 may disrupt bile acid homeostasis and is one hypothesized risk factor for the development of drug-induced liver injury (DILI). Therefore, identifying potential MRP3 inhibitors could help mitigate the occurrence of DILI. METHODS: Bayesian models were developed using MRP3 transporter inhibition data for 86 structurally diverse drugs...
February 24, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28208717/final-demonstration-of-the-co-identity-of-lipiarmycin-a3-and-tiacumicin-b-fidaxomicin-through-single-crystal-x-ray-analysis
#12
Stefano Serra, Luciana Malpezzi, Angelo Bedeschi, Claudio Fuganti, Piera Fonte
Lipiarmycin A3 and tiacumicin B possess the same chemical structure and have been considered identical till recently, when some authors have suggested the possibility of a minor difference between the chemical structures of the two antibiotics. In this work we performed a comparative X-ray analysis of lipiarmycin A3 and tiacumicin B. Although the commercial samples of the aforementioned compounds crystallize into two different crystal systems-evidently due to the different crystallization conditions-their chemical structures are identical...
February 8, 2017: Antibiotics
https://www.readbyqxmd.com/read/28196423/fecal-microbiota-transplantation-is-there-a-role-in-the-eradication-of-carbapenem-resistant-klebsiella-pneumoniae-intestinal-carriage
#13
Ana Ponte, Rolando Pinho, Margarida Mota
The authors present the case of a 66-year-old woman with four hospitalizations due to recurrent Clostridium difficile infection (CDI) non responsive to vancomycin and fidaxomicin. Furthermore, intestinal colonization with carbapenem-resistant Klebsiella pneumoniae (CRKP) was identified after a positive stool culture in a screening routinely performed in our center in patients recently hospitalized.
February 15, 2017: Revista Española de Enfermedades Digestivas
https://www.readbyqxmd.com/read/28178052/fecal-microbiota-transplant-for-clostridium-difficile-infection-in-a-pregnant-patient
#14
Bejan J Saeedi, Doree Gardner Morison, Colleen S Kraft, Tanvi Dhere
BACKGROUND: Clostridium difficile infection has been associated with negative outcomes in the general population and in pregnant patients. Fecal microbiota transplant has become the standard for treatment of recurrent as well as refractory C difficile infection. CASE: We present a case of a 28-year-old pregnant woman who presented with recurrent C difficile infection despite treatment with vancomycin and fidaxomicin and underwent a successful fecal microbiota transplant through colonoscopy at 18 weeks of gestation...
March 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28172620/p390-open-label-study-to-evaluate-the-pharmacokinetics-of-fidaxomicin-in-inflammatory-bowel-disease-patients-with-clostridium-difficile-infection-the-profile-study-pharmacokinetics-analysis
#15
C Högenauer, Y Mahida, A Stallmach, P Marteau, G Rydzewska, V Ivashkin, P Gargalianos-Kakolyris, I Michon, N Adomakoh, W Reinisch
No abstract text is available yet for this article.
February 1, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28134686/novel-antibiotics-in-development-to-treat-clostridium-difficile-infection
#16
Eugénie Bassères, Bradley T Endres, Kierra M Dotson, M Jahangir Alam, Kevin W Garey
PURPOSE OF REVIEW: Clostridium difficile infections (CDI) remain a challenge to treat clinically due primarily to limited number of antibiotics available and unacceptably high recurrence rates. Because of this, there has been significant demand for creating innovative therapeutics, which has resulted in the development of several novel antibiotics. RECENT FINDINGS: This review updates seven different antibiotics that are currently in development to treat CDI including fidaxomicin, surotomycin, ridinilazole, ramoplanin, cadazolid, LFF571, and CRS3123...
January 2017: Current Opinion in Gastroenterology
https://www.readbyqxmd.com/read/28120176/fidaxomicin-for-treatment-of-clostridium-difficile-infection-in-clinical-practice-a-prospective-cohort-study-in-a-french-university-hospital
#17
Marie Pichenot, Rozenn Héquette-Ruz, Remi Le Guern, Bruno Grandbastien, Clément Charlet, Frédéric Wallet, Sophie Schiettecatte, Fanny Loeuillet, Benoit Guery, Tatiana Galperine
PURPOSE: Two randomized controlled trials (RCTs) showed the non-inferiority of fidaxomicin compared with vancomycin for Clostridium difficile infection (CDI) treatment and its superiority regarding recurrence rate. The aim of this study was to evaluate fidaxomicin's efficacy in clinical practice. METHODS: This single-center prospective cohort study included hospitalized patients treated with fidaxomicin for CDI. Demographic, clinical and biological data were collected...
January 24, 2017: Infection
https://www.readbyqxmd.com/read/28116471/-gastrointestinal-infections
#18
C Lübbert, R Mutters
Infectious diarrhea is one of the most common diseases. This article summarizes the current state of the diagnostics and treatment and includes the most important pathogens, i.e. Norovirus, Rotavirus, Campylobacter, Salmonella, Shigella and pathogenic Escherichia coli. Infections caused by toxin-producing strains of Clostridium difficile are described in more detail due to the increasing importance. Symptomatic therapy is still the most important component of treatment. Empirical antibiotic therapy is reserved for severely ill patients with a high stool frequency, fever, bloody diarrhea, underlying immune deficiency or significant comorbidities...
February 2017: Der Internist
https://www.readbyqxmd.com/read/28103289/cost-effectiveness-analysis-of-five-competing-strategies-for-the-management-of-multiple-recurrent-community-onset-clostridium-difficile-infection-in-france
#19
Emilie Baro, Tatiana Galperine, Fanette Denies, Damien Lannoy, Xavier Lenne, Pascal Odou, Benoit Guery, Benoit Dervaux
BACKGROUND: Clostridium difficile infection (CDI) is characterized by high rates of recurrence, resulting in substantial health care costs. The aim of this study was to analyze the cost-effectiveness of treatments for the management of second recurrence of community-onset CDI in France. METHODS: We developed a decision-analytic simulation model to compare 5 treatments for the management of second recurrence of community-onset CDI: pulsed-tapered vancomycin, fidaxomicin, fecal microbiota transplantation (FMT) via colonoscopy, FMT via duodenal infusion, and FMT via enema...
2017: PloS One
https://www.readbyqxmd.com/read/28096550/the-ups-and-downs-of-drug-discovery-the-early-history-of-fidaxomicin
#20
James B McAlpine
The path from antibiotic compound discovery to the market is marked by many potholes and its negotiation is often dependent on luck and persistence. Perhaps the prime example of this is the case of the development of tiacumicin B to Fidaxomicin, where both parameters were critical and the path was particularly circuitous.The Journal of Antibiotics advance online publication, 18 January 2017; doi:10.1038/ja.2016.157.
January 18, 2017: Journal of Antibiotics
keyword
keyword
23034
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"